-
October 1, 2018
LOXO-292 Safe, Effective for RET-Altered Non-Small Cell Lung Cancer Bookmark
Emma Shtivelman, PhDExcerpt from Healio:
“LOXO-292 appeared well tolerated and demonstrated antitumor activity among patients with heavily pretreated RET fusion-positive non-small cell lung cancer, according to updated interim results of a global, phase 1/phase 2 trial presented at International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.
“Researchers reported initial clinical data from the LIBRETTO-001 dose escalation/expansion study of LOXO-292 (Loxo Oncology) — an oral and selective agent in clinical development for cancers that harbor abnormalities in the rearranged during transfection (RET) kinase — at ASCO Annual Meeting in June.”
Go to full article published by Healio on Sep 27, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
October 1, 2018
Novel Agent Active in ROS1-Mutant NSCLC Bookmark
Emma Shtivelman, PhDExcerpt from MedPage Today:
“Three-fourths of patients with ROS1-positive non-small cell lung cancer (NSCLC) had objective responses lasting an average of 2 years with an investigational multikinase inhibitor, a preliminary trial showed.
“Overall, 41 of 53 patients responded to treatment with entrectinib, including 17 of 33 patients with central nervous system (CNS) metastases at baseline. Responses had a median duration of 24.6 months among patients without CNS metastases and 13.6 months among those with CNS metastases.”
Go to full article published by MedPage Today on Sep 25, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
October 1, 2018
AstraZeneca Buoyed as Imfinzi Cuts Lung Cancer Deaths by a Third Bookmark
Emma Shtivelman, PhDExcerpt from Reuters:
“AstraZeneca’s immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease.
“The encouraging overall survival data boosts prospects for a medicine that was approved this week in Europe and has already had a promising U.S. commercial launch, based on its ability to slow disease progression.”
Go to full article published by Reuters on Sep 25, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
October 1, 2018
Roche’s Tecentriq, Trailing Rival Drugs, Lifts Lung Cancer Survival Bookmark
Emma Shtivelman, PhDExcerpt from Reuters:
“A drug cocktail with Roche’s Tecentriq added two months to small-cell lung cancer patients’ lives, according to a study, aiding the Swiss group’s bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.
“Patients with untreated extensive-stage small-cell lung cancer (SCLC), where cancer has spread, lived a median 12.3 months after getting Tecentriq plus chemotherapy.”
Go to full article published by Reuters on Sep 25, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
October 1, 2018
Pembrolizumab Alone or With Chemotherapy for PD-L1–Positive NSCLC? Bookmark
Emma Shtivelman, PhDExcerpt from Cancer Network:
“Researchers found that in patients with non–small-cell lung cancer (NSCLC) and a Tumor Proportion Score (TPS) ≥ 50, pembrolizumab plus chemotherapy failed to improve overall survival (OS) or progression-free survival (PFS) compared with pembrolizumab alone.
“Results from the study were presented in a poster presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer, held September 23–26 in Toronto.”
Go to full article published by Cancer Network on Sep 24, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
October 1, 2018
Brigatinib Superior to Standard of Care Crizotinib in ALK+ NSCLC Bookmark
Emma Shtivelman, PhDExcerpt from Targeted Oncology:
“Adult patients with ALK-positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor experienced a more than 50% reduction in the risk of disease progression or death with treatment with brigatinib (Alunbrig), compared with the first-line standard of care, crizotinib.
“Brigatinib demonstrated superior progression-free survival (PFS) compared with crizotinib, corresponding to a 51% reduction in the risk of disease progression or death (HR, 0.49; 95% CI, 0.33-74; P = .0007), according to first interim analysis results presented at the 19th World Conference on Lung Cancer and simultaneously published in the New England Journal of Medicine.”
Go to full article published by Targeted Oncology on Sep 26, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
September 25, 2018
Hyperprogression in NSCLC Patients With PD-1/PD-L1 Inhibitors Bookmark
Emma Shtivelman, PhDExcerpt from Cancer Network:
“Hyperprogressive disease (HPD) occurred more commonly among patients with pretreated non-small cell lung cancer (NSCLC) receiving PD-1 (programmed cell death protein 1)/PD-L1 (ligand 1) inhibitors than in patients treated with chemotherapy, according to the results of a study published in JAMA Oncology.
“Among those patients with hyperprogressive disease – defined as disease progression at first evaluation with a variation per month exceeding 50% – treated with immunotherapy there was a higher metastatic burden and poorer prognosis, compared with patients without hyperprogressive disease.”
Go to full article published by Cancer Network on Sep 21, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
September 18, 2018
Laser Interstitial Thermal Therapy Shows Promise for Glioblastomas Bookmark
Emma Shtivelman, PhDExcerpt from Cancer Network:
“Magnetic resonance imaging-guided laser interstitial thermal therapy (LITT) appears to be safe and effective for glioblastomas in select patients and may add an average of 2 months to life expectancy compared with the current standard of care, according to a new report published in the journal Neurosurgery.
” ‘We showed that the procedure is well tolerated and that recurrent patients had a meaningful clinical benefit that seems to be better when compared with previously published data on the current standard of care,’ said Eric Leuthardt, MD, senior study author and a professor of neurosurgery, neuroscience, biomedical engineering, and mechanical engineering & applied science at Washington University School of Medicine in St. Louis, Missouri.”
Go to full article published by Cancer Network on Sep 7, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
September 18, 2018
Studies Confirm Osimertinib Activity in Brain Mets Bookmark
Emma Shtivelman, PhDExcerpt from MedPage Today:
“The resistance mutation-targeting EGFR inhibitor osimertinib (Tagrisso) demonstrated superior activity against central nervous system (CNS) metastases as compared with chemotherapy or nonselective EGFR inhibitors, two randomized trials of patients with lung cancer showed.
“In a comparison involving patients with untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC), the median CNS progression-free survival (PFS) was not reached in patients who received osimertinib or a first-generation EGFR inhibitor. However, the available data favored the osimertinib arm (95% CI 16.5 months to not reached versus 13.9 months to not reached, HR 0.48, 95% CI 0.26-0.86, P=0.014). Osimertinib also led to a higher response rate.”
Go to full article published by MedPage Today on Aug 31, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
September 17, 2018
Options to Treat a Glioblastoma
With: Al Musella, DPMPlease see our updated version of this article from Oct 1, 2020. A Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY; email: musella@virtualtrials.com, phone: 888-295-4740 Q: You direct an established foundation that supports research and information about brain tumors. What would you do if you yourself were diagnosed with a glioblastoma multiforme (GBM)? A: Now… Read more »
Treatment Options
Learn about the latest treatments for advanced cancer. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, cancer vaccines, modified viruses, and more.
